| ID Source | ID |
|---|---|
| PubMed CID | 16837 |
| CHEMBL ID | 1360840 |
| CHEMBL ID | 2356984 |
| CHEBI ID | 135053 |
| SCHEMBL ID | 27117 |
| SCHEMBL ID | 27116 |
| MeSH ID | M0066396 |
| Synonym |
|---|
| carmurit |
| nsc-190374 |
| diamazol |
| ethoxazene |
| 1, 4-[(4-ethoxyphenyl)azo]- |
| cystural |
| s. n. 612 |
| m-phenylenediamine, 4-[(p-ethoxyphenyl)azo]- |
| 4-[(p-ethoxyphenyl)azo]-m-phenylenediamine |
| chrysoidine, 4'-ethoxy- |
| 94-10-0 |
| sn 612 |
| p-ethoxychrysoidine |
| 2,4-diamino-4'-ethoxyazobenzene |
| p-ethoxy-2,4-diaminoazobenzene |
| serenium |
| cystural b |
| 4'-ethoxy-2,4-diaminoazobenzene |
| pyraseptic |
| wln: zr cz dnunr do2 |
| 4-p-phenetylazo-m-phenylenediamine |
| diaphenyl |
| salvuron |
| urocarmin |
| nsc190374 |
| brn 1843191 |
| etoxazene [inn] |
| nsc 190374 |
| 4-(p-ethoxyphenylazo)-m-phenylenediamine |
| acidotest |
| m-phenylenediamine, 4-(p-ethoxyphenylazo)- |
| etoxazeno [inn-spanish] |
| einecs 202-304-0 |
| etoxazenum [inn-latin] |
| 1,3-benzenediamine, 4-((4-ethoxyphenyl)azo)- |
| m-phenylenediamine, {4-[(p-ethoxyphenyl)azo]-,} monohydrochloride |
| 4-[(e)-(4-ethoxyphenyl)azo]benzene-1,3-diamine |
| 4-((4-ethoxyphenyl)diazenyl)-1,3-benzenediamine |
| serenium hydrochloride |
| 4-(p-ethoxyphenylazo)-m-phenylenediamine, hydrochloride |
| {4-[(p-ethoxyphenyl)azo]-m-phenylenediamine} monohydrochloride |
| nsc7214 |
| etoxazene |
| 4-[(e)-(4-ethoxyphenyl)diazenyl]-1,3-benzenediamine- |
| 1, 3-benzenediamine, {4-[(4-ethoxyphenyl)azo]-,} monohydrochloride |
| {4-[(p-ethoxyphenyl)azo]-m-phenylenediamine} hydrochloride |
| NCGC00160548-01 |
| CHEBI:135053 |
| 4-[(4-ethoxyphenyl)diazenyl]benzene-1,3-diamine |
| AKOS003621149 |
| etoxazenum |
| unii-u1t1yz4796 |
| 4-16-00-00562 (beilstein handbook reference) |
| u1t1yz4796 , |
| etoxazeno |
| dtxcid3026223 |
| tox21_111891 |
| dtxsid5046223 , |
| cas-94-10-0 |
| sn-612 |
| CHEMBL1360840 |
| etoxazene [who-dd] |
| 4-((4-ethoxyphenyl)azo)-1,3-benzenediamine |
| ethoxazene [mi] |
| 4-p-phenethylazo-m-phenylenediamine |
| 4-((p-ethoxyphenyl)azo)-m-phenylenediamine |
| smr004701088 |
| MLS006010006 |
| SCHEMBL27117 |
| SCHEMBL27116 |
| p-ethoxychrysoidin |
| CHEMBL2356984 |
| sr-01000944445 |
| SR-01000944445-1 |
| 4-(4-ethoxy-phenylazo)-benzene-1,3-diamine |
| p-athoxychrysoidin |
| 1,3-benzenediamine,4-[2-(4-ethoxyphenyl)diazenyl]- |
| AKOS032958017 |
| (e)-4-((4-ethoxyphenyl)diazenyl)benzene-1,3-diamine |
| Q27290563 |
| 1238467-62-3 |
| DTXSID001043724 |
| 4-[(1e)-2-(4-ethoxyphenyl)diazenyl]-1,3-benzenediamine |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| azobenzenes | Any member of the wide class of molecules that share the core azobenzene structure, comprising two phenyl rings linked by a N=N double bond, which may have different functional groups extending from the rings. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 25.1189 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 0.2031 | 0.0072 | 15.7588 | 89.3584 | AID624030 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 50.1187 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 23.8723 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 0.6696 | 0.0002 | 21.2231 | 8,912.5098 | AID743040; AID743042; AID743054 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 1.3180 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743079; AID743080; AID743091 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 0.9719 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.2113 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 15.8489 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 11.4695 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 9.4563 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 28.6954 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 9.4392 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 0.2025 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 0.1679 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1057862 | Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| AID1057863 | Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability after 5 days by calcein-AM staining-based fluorescence assay | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| AID1057864 | Ratio of LC50 for dividing mouse ScN2a-cl3 cells to EC50 for inhibition of RML prion protein | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||